对于耐药焦点的拉莫特里金补充疗法
Mariangela Panebianco1, Rebecca Bresnahan1, Anthony G Marson1,2,3
1Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
The Cochrane database of systematic reviews
|December 11, 2023
概括
添加拉莫特里金可能会减少耐药焦点的发作频率. 然而,它可能会增加,头,恶心和双眼视的风险,与安慰剂相比,其戒断率与安慰剂相似.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 影响0.5%至1%的人口,近30%的病例是耐药的.
- 拉莫特里金是第二代抗发作药物,作为辅助疗法使用.
研究的目的:
- 评估添加剂拉莫特里金与安慰剂在耐药焦点中的益处和危害.
主要方法:
- 进行了随机对照试验 (RCT) 的系统审查.
- 在科克伦研究登记册 (CRS Web) 和MEDLINE进行了搜索,截至2022年10月.
- 主要结局是发作频率减少50%或更多;次要结局包括不良反应和停止治疗.
主要成果:
- 拉莫可能会增加实现50%或更大的发作频率减少的可能性 (RR 1.80,95% CI 1.45至2.23).
- 与拉莫特里金一起观察到,头,恶心和双眼视的风险增加.
- 在lamotrigine和安慰剂之间,治疗中断风险几乎没有差异.
结论:
- 添加拉莫特里金可能有效降低抗药性焦点发作频率.
- 与lamotrigine相关的常见不良反应包括心力衰竭,头,双眼视和恶心.
- 需要进一步的研究来评估长期影响,并将拉莫特林与其他附加治疗方法进行比较.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
310
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
310
Antiepileptic Drugs: GABAergic Pathway Potentiators
413
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
413
Antiepileptic Drugs: Sodium Channel Blockers
585
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
585
Antiepileptic Drugs: Calcium Channel Blockers
412
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
412


